Humacyte Stock Today
| HUMAW Stock | USD 0.12 0.03 33.19% |
PerformanceWeak
| Odds Of DistressRisky
|
Humacyte is selling for under 0.12 as of the 20th of February 2026; that is 33.19 percent increase since the beginning of the trading day. The stock's lowest day price was 0.0901. Humacyte has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 22nd of November 2025 and ending today, the 20th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of November 2020 | Classification Health Care |
Humacyte is entity of United States. It is traded as Stock on NASDAQ exchange. More on Humacyte
Moving against Humacyte Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Humacyte Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBy employing borrowed capital, Humacyte can potentially magnify investment returns. Examining the debt-to-assets ratio offers investors perspective on Humacyte's use of financial leverage and reveals what portion of Humacyte's asset base relies on creditor financing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Humacyte (HUMAW) is traded on NASDAQ Exchange in USA and employs 218 people. Humacyte is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
Humacyte generates negative cash flow from operations
Check Humacyte Probability Of Bankruptcy
Humacyte Historical Income Statement
Humacyte Stock Against Markets
Humacyte Corporate Management
| MS MS | Chief Officer | Profile | |
| Dale Sander | Chief CFO | Profile | |
| Heather Connelly | Senior Quality | Profile | |
| William Scheessele | Chief Officer | Profile | |
| Lisa Molyneux | Executive Analysis | Profile | |
| Shamik MD | Chief Officer | Profile |
Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.